Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide with Chemoimmunotherapy for Relapsed/Refractory Aggressive B-cell Lymphoma
NCT01788189Phase 2Completed
- Sponsor
- Universitätsmedizin Essen
- Start
- Jan 2013
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in aggressive B-cell lymphoma, sponsored by Universitätsmedizin Essen. Started Jan 2013; status: completed.
02
Drugs
lenalidomide
03
Conditions
aggressive B-cell lymphoma
Beyond the preview
Go deeper on NCT01788189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01788189.